Asbt inhibitors in the treatment of renal diseases
US-2024207286-A1 · Jun 27, 2024 · US
Glycodendrimers of polypropyletherimine
US9453040B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9453040-B2 |
| Application number | US-201113818580-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 22, 2011 |
| Priority date | Aug 24, 2010 |
| Publication date | Sep 27, 2016 |
| Grant date | Sep 27, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting on average in the range of 9 to 64 terminal carboxylic acid groups, and b) conjugated to said core in the range of 2 to 8 amino sugars or a sulphate amino sugar selected from the group consisting of glucosamine, N-acetyl glucosamine, mannosamine, N-acetylmannosamine, galactosamine, a sulphate of any one of the same and a combination thereof, wherein each sugar is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extends to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic uses of the molecules, populations and compositions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A glycodendrimer comprising: a) a non-toxic generation 3 dendrimer polypropyletherimine core supporting 16 terminal carboxylic acid groups, wherein the dendrimer polypropyletherimine core has a central atom which is oxygen, and b) conjugated to said core 2, 3, 4 or 5 glucosamine molecures, wherein each glucosamine molecule is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group.…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9453040B2 cover?
- A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting on average in the range of 9 to 64 terminal carboxylic acid groups, and b) conjugated to said core in the range of 2 to 8 amino sugars or a sulphate amino sugar selected from the group consisting of glucosamine, N-acetyl glucosamine, mannosamine, N-acetylmannosamine, galactosamine, a sulphate of any one o…
- Who is the assignee on this patent?
- Shaunak Sunil, Teo Ian Alfred, Imp Innovations Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07H15/26. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).